Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Population: STEP 1 • To assess the global safety of the combination of palbociclib + endocrine therapy in the whole population of patients, throughout the study, including the potential sequential administration of fulvestrant plus palbociclib, with focus on hematological toxicities. Population: STEP 2 • To assess whether a change of the hormone therapy associated with palbociclib (namely, an early switch from aromatase inhibitor with palbociclib to fulvestrant with palbociclib following ctDNA detection) will benefit patients in which rising ESR1 mutations are detected during treatment with palbociclib and aromatase inhibitor.
Critère d'inclusion
- HER-2 negative metastatic breast cancer